Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.
Long-term follow-up of a single-drug leukemia treatment reveals how cancer cells evolve resistance, guiding doctors toward the best salvage therapies for individual patients.
This Peter MacCallum Cancer Centre study reports long-term follow-up of continuous venetoclax monotherapy in relapsed/refractory CLL, characterizing the durability of responses over several years and the molecular landscape of emerging resistance including BCL-2 mutations and clonal evolution. These data inform clinical decision-making for patients on continuous venetoclax and guide resistance-based salvage therapy selection.
What the study was
- Study design
- Prospective longitudinal follow-up cohort of venetoclax-treated patients
- Population
- Relapsed/refractory CLL patients treated with continuous venetoclax monotherapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood advances
Why it surfaced
Long-term outcomes data on continuous venetoclax monotherapy in relapsed CLL from Roberts/Anderson group (Peter MacCallum). Characterizes late relapse patterns and resistance mechanisms — directly informs real-world prescribing and post-venetoclax sequencing.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.